Cat. #151345
Anti-Leu2 [C8/144B] mAb
Cat. #: 151345
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Leu2 (CD8)
Class: Monoclonal
Application: IHC ; IF ; IP ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Jacqueline Cordell
Institute: University of Oxford
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Leu2 [C8/144B] mAb
- Alternate name: CD8a Molecule; T-Lymphocyte Differentiation Antigen T8/Leu-2; CD8 Antigen; Alpha Polypeptide (P32); MAL; T-Cell Surface Glycoprotein CD8 Alpha Chain; Leu2 T-Lymphocyte Antigen; OKT8 T-Cell Antigen; T-Cell Antigen Leu2; T8 T-Cell Antigen; CD8a Antigen; Leu2; P32
- Cancer: Blood cancer
- Cancers detailed: Leukemia;Lymphoma
- Research fields: Immunology;Stem cell biology
- Clone: C8/144B
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: IHC ; IF ; IP ; WB
- Description: C8/144B can be used to detect these cells in tissue sections and also their neoplastic counterparts.
- Immunogen: Synthetic peptide (the 13 C-terminal residues of the cytoplasmic domain of human CD8a)
- Isotype: IgG1
- Myeloma used: P3/NS1/1-Ag4.1
Target Details
- Target: Leu2 (CD8)
- Target background: CD8 is a T cell co-receptor that recognises, together with the T cell receptor, MHC class I molecules. CD8 is present on human suppressor/cytotoxic T cells which make up 30% of circulating T cells.
Applications
- Application: IHC ; IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- van Gool et al. 2015. Clin Cancer Res. 21(14):3347-55. PMID: 25878334.
- POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
- Harlin et al. 2009. Cancer Res. 69(7):3077-85. PMID: 19293190.
- Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
- Sato et al. 2005. Proc Natl Acad Sci U S A. 102(51):18538-43. PMID: 16344461.
- Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
- Mason et al. 1992. J Clin Pathol. 45(12):1084-8. PMID: 1479035.
- Immunohistological detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence.
